BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 12620664)

  • 1. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
    Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
    Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
    Boichot E; Wallace JL; Germain N; Corbel M; Lugnier C; Lagente V; Bourguignon JJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):647-53. PubMed ID: 10640302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
    Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
    J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide analogs and PDE4 inhibition.
    Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.
    Hulme C; Moriarty K; Huang FC; Mason J; McGarry D; Labaudiniere R; Souness J; Djuric S
    Bioorg Med Chem Lett; 1998 Feb; 8(4):399-404. PubMed ID: 9871693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic studies on selective type 4 phosphodiesterase (PDE 4) inhibitors. 1. Structure-activity relationships and pharmacological evaluation of 1,8-naphthyridin-2(1H)-one derivatives.
    Takayama K; Iwata M; Hisamichi H; Okamoto Y; Aoki M; Niwa A
    Chem Pharm Bull (Tokyo); 2002 Aug; 50(8):1050-9. PubMed ID: 12192136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
    Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
    Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors.
    Rhee CK; Kim JH; Suh BC; Xiang MX; Youn YS; Bang WY; Kim E; Shin JK; Lee Y
    Arch Pharm Res; 1999 Apr; 22(2):202-7. PubMed ID: 10230513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
    Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase.
    Floreani M; Fossa P; Gessi S; Mosti L; Borea PA; Dorigo P
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):109-18. PubMed ID: 12595951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
    Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
    Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
    Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.
    Huang Y; Wu XN; Zhou Q; Wu Y; Zheng D; Li Z; Guo L; Luo HB
    J Med Chem; 2020 Dec; 63(24):15852-15863. PubMed ID: 33291877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
    Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.